Aceclidine

證據等級: L5

預測適應症: 0 個

Aceclidine: Repurposing Evaluation — Insufficient Evidence Pack

One-Sentence Summary

Aceclidine (DB13262) is a pharmacological compound for which original indication data is not captured in this Evidence Pack. The TxGNN pipeline returned no predicted indications for this drug, and critical data including mechanism of action, safety warnings, and regulatory information are all absent. This report documents the current data status and outlines the remediation steps required before a repurposing evaluation can proceed.

Quick Overview

Item	Content
Original Indication	No data available
Predicted New Indication	No TxGNN predictions returned
TxGNN Prediction Score	N/A
Evidence Level	L5 — Model prediction unavailable; no supporting studies
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No mechanism of action data is available for Aceclidine in this Evidence Pack (Data Gap DG002). The DrugBank query on 2026-03-24 returned a record (result count: 1), confirming the compound exists in DrugBank under ID DB13262, but MOA details were not extracted into the Evidence Pack.

Without a confirmed MOA and without any TxGNN predicted indications (predicted_indications: []), it is not possible to construct a mechanistic rationale linking Aceclidine to any new disease indication at this stage.

A repurposing rationale analysis should be re-attempted once the TxGNN prediction pipeline is re-run and the DrugBank MOA is retrieved.

Clinical Trial Evidence

Currently no related clinical trials registered for any predicted indication, as no predicted indications are available in this Evidence Pack.

Literature Evidence

Currently no related literature available, as no predicted indications are available in this Evidence Pack.

US Market Information

Aceclidine has no NDA filings and is not currently marketed in the United States. No license records are available.

Safety Considerations

Please refer to the package insert for safety information.

Note: The TFDA label (warnings and contraindications) was flagged as a Blocking data gap (DG001) and could not be retrieved for this Evidence Pack. The DDI query returned no interactions. All safety fields are currently unpopulated.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for Aceclidine is structurally incomplete — the TxGNN pipeline returned zero predicted indications, and two blocking/high-severity data gaps prevent any safety or mechanistic analysis from proceeding.

To proceed, the following is needed:

[Blocking — DG001] Retrieve TFDA label PDF and parse warnings/contraindications to unblock the S1 safety screen
[High — DG002] Query DrugBank API to extract the mechanism of action (MOA) for DB13262 and populate original_moa
[Required] Re-run the TxGNN prediction pipeline to generate predicted_indications; investigate why the current run returned an empty array (possible causes: drug not found in knowledge graph, mapping failure, or filtering threshold too strict)
[Recommended] Confirm original indications via DrugBank indication field or published pharmacological references to complete the drug profile before re-evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.